May 14, 2024 | Featured, Maryland, News, Science
A team of genetic researchers from the UK, US, and Switzerland has identified a mutation in the gene TMEM216 as a common cause of retinitis pigmentosa (RP) in people with African ancestry. The team estimates that approximately 20-30 percent of all RP patients with...
May 10, 2024 | Featured, Maryland, News, Science
EyeDNA Therapeutics, a subsidiary of Paris-based Coave Therapeutics, reported encouraging 24-month results for 17 adult patients in its Phase ½ PDE6B gene therapy clinical trial underway at Clinique Ophthalmologique, CHU de Nantes, in France. The results were reported...
May 2, 2024 | Featured, Maryland, News, Science
Atsena Therapeutics, a company developing innovative gene therapies for inherited retinal diseases, has reported both structural and functional vision improvements for patients receiving the low dose of the company’s X-linked retinoschisis (XLRS) gene therapy in its...
Apr 19, 2024 | Featured, Maryland, News, Science
SalioGen Therapeutics, a biotechnology company developing therapies for a broad range of conditions, including inherited retinal diseases, has announced development of SGT-1001, an emerging Stargardt disease (ABCA4 mutations) therapy, as the lead program for advancing...
Feb 21, 2024 | Featured, Maryland, News, Science
The biotechnology company is preparing to launch a pivotal, Phase 3 clinical trial in the US for its emerging jCell therapy. The company’s announcement came after a successful planning meeting with the US Food & Drug Administration. Participant enrollment for the...
Feb 9, 2024 | Featured, Maryland, News, Science
Beacon Therapeutics has reported vision improvements for five of eight patients receiving the high dose of its X-linked retinitis pigmentosa (XLRP) gene therapy in the Phase 2 SKYLINE clinical trial. Known as AGTC-501, the emerging gene therapy is for patients with...
